Skip to main content

The Next Wave for Virus Testing Stocks (NASDAQ: HOLX) (OTC US: ALST) (NASDAQ: FLGT)

By: OTC

While vaccines are rolling out rapidly around the developed world, and uptake is expected to produce some version of herd immunity within the next six months, scientists are acclimating to the idea that we may be locked in a long-term battle with Covid-19 that could last years or even decades.

While the pandemic health crisis may recede from the front page during most of that battle, organizations, cities, states, countries, and major institutions will have to maintain a constant vigil and act with well-honed protocols to maintain our advantage in the fight.

One of the most important tools in this war will be rapid results testing resources, which is set to become a major industry with a very bright future.

As such, we take a look at a few of the more interesting names in that space, including: Hologic Inc. (NASDAQ  HOLX), Allstar Health Brands Inc. (OTCMKTS: ALST), and Fulgent Genetics Inc (NASDAQ: FLGT).

 

Fulgent Genetics Inc. (NASDAQ: FLGT) provides genetic testing services to physicians with clinically actionable diagnostic information.

The company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally.

Fulgent Genetics Inc. (NASDAQ: FLGT) recently announced that the Company has extended its partnership with the New York City Department of Education (or “NYC DOE”) and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.

“We have been working with the teams in New York City over the last several weeks, which has been going extremely well. The ongoing success of our COVID-19 testing program is a major testament to the hard work of the teams in New York City and the Fulgent staff involved in the project,” said Brandon Perthuis, Fulgent’s Chief Commercial Officer.

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action FLGT shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -7% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities.

Fulgent Genetics Inc. (NASDAQ: FLGT) generated sales of $101.7M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 489.1% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($74.9M against $57.7M).

 

Allstar Health Brands Inc. (OTCMKTS: ALST) is the most speculative name in this basket, but it may also end up being the stock with the greatest upside potential simply because it is the least well known and likely has seen the least interest to date.

One of ALST’s core assets at this point is its partnership with TPT Global Tech, a technology and solutions company. The two companies are collaborating to create and distribute the QuickLAB module, a rapid testing solution for Covid-19. The two companies had already recently signed an agreement for Mexico and other Latin American countries through TPT Global Tech’s partner New Orbit Technologies. Now, they have signed an expanded agreement to bring QuickLAB distribution to Canada and US to add to the existing Non-Exclusive Distribution Agreement for Mexico and other Latin American countries.

Allstar Health Brands Inc. (OTCMKTS :ALST) most recently announced it has signed an Agreement with a Consulting group intending to Distribute the COVID-19 suite of testing capabilities and reporting Software AllStar Distributes for TPT Medtech. The new territories include South Africa, Sub-Saharan Africa, Angola and Portugal.

“Our goal is to quickly build on the model we have begun in Jamaica, and now offer rapid and reliable testing solutions to various sectors of the South African economy, including testing in the vast mining industry as well as other sectors of the economy such as tourism and the public in general,” remarked Dr. Daniel Bagi, CEO of AllStar. “We offer a full range of solutions, including the mobile testing labs which can be set-up at the entrance to mines, complete with all the current testing solutions available: PCR, Antigen, and Antibody tests as well as the QuikPASS and Check & Verify software to ensure the testing is validated across several accepted platforms. The added benefit of the software is that once vaccinations begin, the results will also be available on the individual’s ‘COVID19 passport’. We view acceptance and launch in South Africa as a springboard into other countries in Africa, so we are working towards having South Africa as our entry point into the Continent.”

Allstar Health Brands Inc. (OTCMKTS: ALST) generated sales of $178K, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 224.2% on the top line. ALST is surely a more speculative name on this list. But with the company’s recent expansion and partnership, it may also be the most underpriced.

 

Hologic Inc. (NASDAQ: HOLX) frames itself as a diagnostics testing technology company that developed SARS-CoV-2 assays on both its Panther and Panther Fusion systems. Both assays enable labs to run over 1000 tests in 24 hours and attain first results in 3.5 hours or less.

The Panther Fusion SARS-CoV-2 assay is a real-time PCR test, and the Aptima SARS-CoV-2 assay utilizes its proprietary TMA technology. Both assays are intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal wash, and lower respiratory tract specimens (Panther Fusion assay only) obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria.

Hologic Inc. (NASDAQ: HOLX) recently announced a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud’s machine learning (ML) technologies with Hologic’s cutting-edge Genius Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe.

“Hologic has been at the forefront of cervical cancer screening for more than 30 years, and we are building on that legacy with this strategic collaboration,” said Kevin Thornal, President of Hologic’s Diagnostic Solutions Division. “Enhancing our use of AI with Google Cloud’s machine learning capabilities and cloud architecture is the next natural step in this journey forward.”

It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Shares of the stock have powered higher over the past month, rallying roughly 10% in that time on strong overall action.

Hologic Inc. (NASDAQ: HOLX) generated sales of $1.6B, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 19.5% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($868.7M against $1.1B, respectively).

 

DISCLAIMER:  EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  EDM is NOT affiliated in any manner with any company mentioned herein.  EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  EDM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  EDM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed EDM has been compensated ninety five hundred dollars for news coverage of the current press releases issued by Allstar Health Brands Inc by the third party.

EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.

 

 

 

 

 

Media Contact:

EDM Media LLC

Email: IR@EDM.Media

Office: 800-301-7883

EDM.Media

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.